RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. XENE | 0.00 |
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:
XENE) with a Outperform and raises the price target from $80 to $82.